NEW YORK –Diagnostic developer Entopsis is taking its first steps into the cancer space by adapting its multi-analyte detection platform for prostate cancer screening and partnering with national laboratory Genetics Institute of America (GIA).
The Miami -based firm's platform, called OpsisDx, uses a glass slide with 70 hydrogel structures that bind to molecules in a patient's liquid sample and create a colorimetric signature when heated that reflect biometric changes in a patient's body.